menu
    • menu
    [{"orgOrder":0,"company":"Nucelx","sponsor":"BIRD Foundation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"iTOL-102","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Nucelx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nucelx \/ BIRD Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Nucelx \/ BIRD Foundation"},{"orgOrder":0,"company":"Nucelx","sponsor":"Kadimastem","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Merger","leadProduct":"AstroRx","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Nucelx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nucelx \/ Kadimastem","highestDevelopmentStatusID":"7","companyTruncated":"Nucelx \/ Kadimastem"}]

    Find Clinical Drug Pipeline Developments & Deals by Nucelx

    Menu

    Nucelx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nucelx

                            Switzerland arrow
                            COMPAMED
                            Not Confirmed

                            Nucelx

                            Switzerland arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Kadimastem

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            NLS Pharmaceutics and Kadimastem Complete Merger

                            Details : The proposed merger involves AstroRx, a cell & gene therapy company, to advance treatments for central nervous system disorders.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 30, 2025

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Kadimastem

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nucelx

                            Switzerland arrow
                            COMPAMED
                            Not Confirmed

                            Nucelx

                            Switzerland arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iTOL-102

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : BIRD Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NLS and Kadimastem Continue BIRD Support for ITOL-102 Diabetes Program

                            Details : The funding will support the development of iTOL-102, a cell & gene therapy targeting insulin/glucagon for Type 1 Diabetes.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 29, 2025

                            Lead Product(s) : iTOL-102

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : BIRD Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth